Sagimet Biosciences Series A (SGMT) News
NASDAQ: SGMTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
SGMT news summary
We found 2 recent headlines mentioning Sagimet Biosciences Series A (SGMT): 2 in the past week and 2 in the past 30 days, most often from GlobeNewswire, Nasdaq. For price context, SGMT is up 0.11% at $8.93. The most recent story, "Sagimet To Present Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne and Mechanistic Data at the 2026 Fall Clinical Dermatology Conference", was published by GlobeNewswire on Oct 9, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Sagimet Biosciences Series A headlines
- Sagimet To Present Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne and Mechanistic Data at the 2026 Fall Clinical Dermatology ConferenceSagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that the…GlobeNewswire
- Notable Monday Option Activity: ONT, NET, SGMTLooking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Onterris Inc (Symbol: ONT), where a total volume of 5,437 contracts has been…NasdaqONT, NET, SGMT